Radiopharm Theranostics (ASX:RAD, Nasdaq:RADX) Receives AUD 4.49Mn R&D Tax Refund

July 16, 2025 11:54 AM AEST | By Sonal Goyal

Google News:

Radiopharm Theranostics (ASX:RAD, Nasdaq:RADX) Receives AUD 4.49Mn R&D Tax Refund — Image source: Company website

Recent News

Zoomex and Haas F1 Launch Global Interview Series: Engine On: Zoomex ×...

CSL (ASX:CSL) and Pro Medicus (ASX:PME): Healthcare Innovators Shaping...

HYROX Returns to Hong Kong with Cigna Healthcare as Title Sponsor for...

Sonic Healthcare (ASX:SHL) Stands Tall in ASX 300 with Stable Demand a...

Highlights

Radiopharm Theranostics received an R&D tax refund of AUD 4.49 million for the 2024 financial year, including AUD 94,559 in interest.

The funds will support the continued development of Radiopharm’s radiopharmaceutical portfolio for therapeutic and diagnostic applications.

Radiopharm is advancing a pipeline that includes one Phase 2 and three Phase 1 clinical trials that target multiple solid tumour cancers.

Radiopharm Theranostics (ASX:RAD, Nasdaq: RADX) has received a research and development (R&D) tax refund of AUD 4,485,434 for the 2024 financial year, including AUD 94,559 in interest. The refund was issued through Australia’s R&D Tax Incentive, a government program that reimburses eligible companies with up to 43.5% of their approved R&D expenses.

The company noted that the funds will support the ongoing development of its radiopharmaceutical portfolio, which focuses on both diagnostic and therapeutic applications in oncology.

About the Company

Radiopharm is a clinical-stage biopharmaceutical company that is engaged in the development of innovative oncology radiopharmaceuticals. Its diverse pipeline includes platform technologies such as peptides, monoclonal antibodies and small molecules designed for targeted cancer detection and treatment.

The company is currently conducting four clinical trials include three Phase 1 and one Phase 2 studies, targeting solid tumour cancers, including brain, lung and breast cancers.

RAD shares were trading 4.54% higher at AUD 0.023 per share at the time of writing on 16 July 2025.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.